<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03077048</url>
  </required_header>
  <id_info>
    <org_study_id>Keto-022-CP1</org_study_id>
    <secondary_id>2016-003854-34</secondary_id>
    <nct_id>NCT03077048</nct_id>
  </id_info>
  <brief_title>Short-term Metabolic Effects of Ketosteril® Supplemented Low Protein Diet in Pre-dialysis Chronic Kidney Disease (CKD) Patients</brief_title>
  <acronym>CKD</acronym>
  <official_title>Short-term Metabolic Effects of Ketosteril® Supplemented Low Protein Diet in Pre-dialysis CKD Patients - A Randomized, Controlled, Open-labelled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fresenius Kabi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>EastHORN Clinical Services in CEE</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MLM Medical Labs GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ALS Czech Republic, s.r.o.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PCG Clinical Services AB</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fresenius Kabi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Supplementation of ketoanalogues of essential amino acids improves the protein quality of
      protein restricted diets without burdening the kidneys. The ketoanalogues are transaminated
      by aminotransferases to the corresponding amino acids by incorporating nitrogen from amino
      groups derived from endogenous amino acid degradation. Therefore, less nitrogen needs to be
      excreted and the kidney's workload is reduced.

      The purpose of the trial is to investigate the impact of Ketosteril® supplementation on A)
      nutritional safety and tolerance of a low protein diet (LPD) (0.6 g protein/kg bodyweight
      (BW)/day)and B) net protein synthesis in pre-dialysis CKD patients.

      Changes of urea in serum and urine will be assessed under controlled metabolic balance
      conditions in non-dialysed CKD patients consuming a LPD supplemented with Ketosteril® at 1
      tablet/5 kg body weight/day compared to the same, isonitrogenous and isocaloric diet without
      Ketosteril®.

      Changes in protein synthesis and degradation at the defined protein intake with or without
      Ketosteril® supplementation will be investigated - based on nitrogen balance, normalized
      protein catabolic rates as well as blood levels of defined proteins as surrogate markers for
      net protein synthesis and anabolic signaling.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 30, 2017</start_date>
  <completion_date type="Actual">May 2, 2018</completion_date>
  <primary_completion_date type="Actual">April 27, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Impact of Ketosteril® on the generation of nitrogenous waste products</measure>
    <time_frame>10 days</time_frame>
    <description>Serum urea</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Impact of Ketosteril® on the generation of nitrogenous waste products</measure>
    <time_frame>10 days</time_frame>
    <description>Urine urea</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Impact of Ketosteril® on the generation of nitrogenous waste products</measure>
    <time_frame>10 days</time_frame>
    <description>Nitrogen balance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Impact of Ketosteril® on the generation of nitrogenous waste products</measure>
    <time_frame>10 days</time_frame>
    <description>Normalized protein catabolic rate (nPCR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Protein metabolism</measure>
    <time_frame>10 days</time_frame>
    <description>Serum total proteins</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Protein metabolism</measure>
    <time_frame>10 days</time_frame>
    <description>Albumin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Protein metabolism</measure>
    <time_frame>10 days</time_frame>
    <description>Transthyretin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Protein metabolism</measure>
    <time_frame>10 days</time_frame>
    <description>Transferrin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Markers of anabolic signaling</measure>
    <time_frame>10 days</time_frame>
    <description>Serum Insulin-like growth factor (IGF)-I</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Markers of anabolic signaling</measure>
    <time_frame>10 days</time_frame>
    <description>Insulin like growth factor (IGF)-II</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Markers of anabolic signaling</measure>
    <time_frame>10 days</time_frame>
    <description>IGF-binding protein 3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>10 days</time_frame>
    <description>Proteinuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>10 days</time_frame>
    <description>Albuminuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>10 days</time_frame>
    <description>Serum and urine creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>10 days</time_frame>
    <description>Serum and urine urea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>10 days</time_frame>
    <description>Serum urea nitrogen (SUN)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>10 days</time_frame>
    <description>Urine nitrogen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>10 days</time_frame>
    <description>Glomerular filtration rate estimated from serum creatinine (eGFR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>10 days</time_frame>
    <description>Albumin-creatinine ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>10 days</time_frame>
    <description>Urea clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional status</measure>
    <time_frame>10 days</time_frame>
    <description>Body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional status</measure>
    <time_frame>10 days</time_frame>
    <description>Body Mass Index (BMI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional status</measure>
    <time_frame>10 days</time_frame>
    <description>Body composition (via Bio Impedance Spectroscopy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional status</measure>
    <time_frame>10 days</time_frame>
    <description>SUN-to-creatinine ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose metabolism</measure>
    <time_frame>10 days</time_frame>
    <description>Fasting blood glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid profile</measure>
    <time_frame>10 days</time_frame>
    <description>Triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid profile</measure>
    <time_frame>10 days</time_frame>
    <description>Cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid profile</measure>
    <time_frame>10 days</time_frame>
    <description>High-density lipoprotein (HDL)/Low-density lipoprotein (LDL)-cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mineral status</measure>
    <time_frame>10 days</time_frame>
    <description>Sodium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mineral status</measure>
    <time_frame>10 days</time_frame>
    <description>Calcium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mineral status</measure>
    <time_frame>10 days</time_frame>
    <description>Potassium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mineral status</measure>
    <time_frame>10 days</time_frame>
    <description>Magnesium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mineral status</measure>
    <time_frame>10 days</time_frame>
    <description>Phosphate (serum and urine)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mineral status</measure>
    <time_frame>10 days</time_frame>
    <description>Alkaline phosphatase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mineral status</measure>
    <time_frame>10 days</time_frame>
    <description>Fibroblast growth factor (FGF)-23</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mineral status</measure>
    <time_frame>10 days</time_frame>
    <description>25-hydroxycholecalciferol (serum)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acid-base balance</measure>
    <time_frame>10 days</time_frame>
    <description>Serum bicarbonate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acid-base balance</measure>
    <time_frame>10 days</time_frame>
    <description>Arterialized venous blood potential of hydrogen (pH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acid-base balance</measure>
    <time_frame>10 days</time_frame>
    <description>Urine pH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation</measure>
    <time_frame>10 days</time_frame>
    <description>Serum C-reactive protein (CRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation</measure>
    <time_frame>10 days</time_frame>
    <description>Serum albumin/CRP ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematology</measure>
    <time_frame>10 days</time_frame>
    <description>Hematocrit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematology</measure>
    <time_frame>10 days</time_frame>
    <description>Hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematology</measure>
    <time_frame>10 days</time_frame>
    <description>Red blood cell (RBC) count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematology</measure>
    <time_frame>10 days</time_frame>
    <description>White blood cell (WBC) count total</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematology</measure>
    <time_frame>10 days</time_frame>
    <description>WBC count differential (lymphocytes, basophils, monocytes, neutrophils, eosinophils)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematology</measure>
    <time_frame>10 days</time_frame>
    <description>Platelet count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematology</measure>
    <time_frame>10 days</time_frame>
    <description>Mean corpuscular hemoglobin (MCH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematology</measure>
    <time_frame>10 days</time_frame>
    <description>Mean corpuscular hemoglobin concentration (MCHC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematology</measure>
    <time_frame>10 days</time_frame>
    <description>Mean corpuscular volume (MCV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation</measure>
    <time_frame>10 days</time_frame>
    <description>Prothrombin time (Quick)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation</measure>
    <time_frame>10 days</time_frame>
    <description>Activated partial thromboplastin time (APTT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation</measure>
    <time_frame>10 days</time_frame>
    <description>International normalized ratio (INR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum chemistry</measure>
    <time_frame>10 days</time_frame>
    <description>Glutamate oxaloacetate transaminase (GOT)/Aspartate aminotransferase (AST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum chemistry</measure>
    <time_frame>10 days</time_frame>
    <description>Glutamate-pyruvate transaminase (GPT)/Alanine transaminase (ALT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum chemistry</measure>
    <time_frame>10 days</time_frame>
    <description>Uric acid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum chemistry</measure>
    <time_frame>10 days</time_frame>
    <description>Creatine kinase (CK)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum chemistry</measure>
    <time_frame>10 days</time_frame>
    <description>Troponin T if CK is elevated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum chemistry</measure>
    <time_frame>10 days</time_frame>
    <description>Chloride</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>52 days</time_frame>
    <description>Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>10 days</time_frame>
    <description>Systolic and diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>10 days</time_frame>
    <description>Pulse rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Renal Insufficiency, Chronic</condition>
  <arm_group>
    <arm_group_label>Low protein diet</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Low protein diet with 0.6 g protein/kg BW/day (20-30% high biological value) and an energy intake of 30-35 kcal/kg BW/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Supplemented low protein diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketosteril® supplemented low protein diet (sLPD), (1 tablet/5 kg BW/day) with 0.6 g protein/kg BW/day (20-30% high biological value) and an energy intake of 30-35 kcal/kg BW/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketosteril®</intervention_name>
    <description>Patients will be randomised to receive isonitrogenous and isocaloric LPD providing 0.6 g protein/kg BW/day and an energy intake of 30-35 kcal/kg BW/day with (test group) or without (control group) intake of Ketosteril® (1 tablet/5 kg BW/day). The control group will get additional food protein to balance the nitrogen content of Ketosteril® The mainly vegetarian diet will be maintained for 10 days.</description>
    <arm_group_label>Supplemented low protein diet</arm_group_label>
    <other_name>EV product code: PRD1170237</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent

          2. Non-dialysed male and female CKD patients with expected start of dialysis ≥ 3 months

          3. eGFR ≥5 to &lt; 30 ml/min/1.73 m2

          4. Stable renal function at least 12 weeks before enrollment, defined by change in serum
             creatinine ≤ 80 µmol/L

          5. Body mass index (BMI): ≥ 22 kg/m² and ≤ 35 kg/m2

          6. Age: ≥ 40 to ≤ 75 years

          7. Eligible physical status of the patient for participation in the study upon assessment
             of the investigator based on medical history, physical examination and clinical
             laboratory parameters

        Exclusion Criteria:

          1. Existing gastrointestinal diseases or pathological findings (e.g. heart, liver, or
             lung failure), which might interfere with the safety, tolerability, absorption and/or
             pharmacokinetics of the active ingredient (e.g. persistent or frequent episodes of
             anorexia, vomiting, or diarrhea)

          2. Active cancer

          3. Diabetes treated with standard pharmacotherapy

          4. HbA1c ≥ 48 mmol/mol, and/or fasting blood glucose ≥ 126 mg/dl (≥ 7 mmol/L))

          5. Evidence of chronic infection or chronic inflammation; evidence of acute infection or
             acute inflammation

          6. C-reactive protein (CRP) &gt; 20 mg/L determined at screening examination

          7. Known allergic reactions to the active ingredients used or to constituents of the
             pharmaceutical preparation

          8. Severe allergies or multiple drug allergies if judged as relevant for the clinical
             trial by the investigator

          9. Patients suffering from hypercalcaemia with a serum calcium ≥ 2.9 mmol/L performed on
             screening examination

         10. Major disorder of amino acid metabolism, e.g. hereditary diseases

         11. Hospitalization within the previous 1 month

         12. Proteinuria &gt; 3 g/day

         13. Regular intensive exercise

         14. Ingestion of creatine supplements within the previous 1 month

         15. Intake of other anabolic or anti catabolic agents within the previous 1 month

         16. Any change of the chronic medication within 1 month before screening

         17. Autosomal dominant polycystic kidney disease (ADPKD)

         18. Positive anti-HIV-test (if positive to be verified by western blot), Hepatitis B
             surface antigen (HBsAG)-test (if positive to be verified by test for hepatitis B core
             antigen (HBc)- Immunoglobulin M (IgM)) or anti-hepatitis C virus (HCV)-test

         19. Current drug or alcohol dependence

         20. Blood donation (including donation of plasma and platelets) or other blood loss of
             more than 400 ml within the last 2 months prior to individual enrolment of the patient

         21. Participation in an interventional clinical trial during the last 2 months prior to
             individual enrolment of the patient

         22. Patients who report a frequent occurrence of migraine attacks (i.e. at least once per
             month)

         23. History of relevant central nervous system (CNS) and/or psychiatric disorders and/or
             currently treated CNS and/or psychiatric disorders

         24. Change in habits of physical activity within the last 2 months for at least 7 days
             (e.g. immobilisation due to bed rest, immobilisation of a leg or other big muscle
             groups)

         25. Positive pregnancy test at screening examination

         26. Pregnant or lactating women

         27. Not willing to apply highly effective contraceptive methods [i.e. combined (estrogen
             and progestogen containing) hormonal contraception e.g. oral, intravaginal,
             transdermal and progestogen-only hormonal contraception e.g. oral, injectable,
             implantable as well as intrauterine device (IUD) and intrauterine hormone-releasing
             system (IUS) in combination with male condom; bilateral tubal occlusion, vasectomised
             partner or sexual abstinence]

         28. Patients suspected or known not to follow instructions

         29. Patients who are unable to understand the written and verbal instructions, in
             particular regarding the risks and inconveniences they will be exposed to during their
             participation in the clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John F Stover, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Fresenius Kabi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomayer Hospital Clinical - Pharmacology Unit (CPU)</name>
      <address>
        <city>Prague</city>
        <zip>140 59</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2017</study_first_submitted>
  <study_first_submitted_qc>March 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2017</study_first_posted>
  <last_update_submitted>May 11, 2018</last_update_submitted>
  <last_update_submitted_qc>May 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CKD</keyword>
  <keyword>Ketosteril</keyword>
  <keyword>keto-acids</keyword>
  <keyword>ketoanalogues</keyword>
  <keyword>Chronic kidney disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

